Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Non-Current Deffered Revenue (2024 - 2025)

Collegium Pharmaceutical (COLL) has 2 years of Non-Current Deffered Revenue data on record, last reported at $9.3 million in Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue fell 7.22% year-over-year to $9.3 million; the TTM value through Sep 2025 reached $9.3 million, down 7.22%, while the annual FY2024 figure was $10.0 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue reached $9.3 million in Q3 2025 per COLL's latest filing, down from $10.0 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $10.0 million in Q3 2024 and bottomed at $9.3 million in Q3 2025.